Lorenza Matarazzo

Lorenza Matarazzo

Auto-generated profile, based on publicly available information

Lorenza Matarazzo

University of Trieste, trieste, Italy

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2013 in Italian Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
RDRiccardo Davanzo
Riccardo Davanzo
SBSara Dal Bo
Sara Dal Bo
JBJenny Burlo Bua
Jenny Burlo Bua
MCMarco Copertino
Marco Copertino
EZElisa Zanelli
Elisa Zanelli
LMLorenza Matarazzo
Lorenza Matarazzo
Introduction: This review provides a synopsis for clinicians on the use of antiepileptic drugs (AEDs) in the breastfeeding mother. Methods: For each AED, we collected all retrievable data from Hale’s “Medications and Mother Milk” (2012), from the LactMed database (2013) of the National Library of Medicine, and from a MedLine Search of relevant studies in the past 10 years. Results: Older AEDs, such as carbamazepine, valproic acid, phenytoin, phenobarbital, primidone are considered to have a good level of safety during lactation, due to the long term clinical experience and the consequent amount of available data from the scientific literature. On the contrary, fewer data are available on the use of new AEDs. Therefore, gabapentin, lamotrigine, oxcarbazepine, vigabatrin, tiagabine, pregabalin, leviracetam and topiramate are compatible with breastfeeding with a less documented safety profile. Ethosuximide, zonisamide and the continue use of clonazepam and diazepam are contraindicated during breastfeeding. Conclusions: Although the current available advice on the use of AEDs during breastfeeding, given by different accredited sources, present some contradictions, most AEDs can be considered safe according to our review.

29 October 2018 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
EGEmmanuel GONZALES
Emmanuel GONZALES
LMLorenza Matarazzo
Lorenza Matarazzo
SFStéphanie Franchi-Abella
Stéphanie Franchi-Abella
ADAlain Dabadie
Alain Dabadie
JCJoseph Cohen
Joseph Cohen
EJEmmanuel Jacquemin
Emmanuel Jacquemin
Oral cholic acid (CA) replacement has been shown to be an effective therapy in children with primary bile acid synthesis defects, which are rare and severe genetic liver diseases. To date there has been no report of the effects of this therapy in children reaching adulthood. The aim of the study was to evaluate the long-term effectiveness and safety of CA therapy. Fifteen patients with either 3β-hydroxy-Δ5-C27-steroid oxidoreductase (3β-HSD) (n = 13) or Δ4–3-oxosteroid 5β-reductase (Δ4–3-oxo-R) (n = 2) deficiency confirmed by mass spectrometry and gene sequencing received oral CA and were followed prospectively. The median age at last follow-up and the median time of follow-up with treatment were 24.3 years (range: 15.3–37.2) and 21.4 years (range: 14.6–24.1), respectively. At last evaluation, physical examination findings and blood laboratory test results were normal in all patients. Liver sonograms were normal in most patients. Mean daily CA dose was 6.9 mg/kg of body weight. Mass spectrometry analysis of urine showed that excretion of the atypical metabolites remained low or traces in amount with CA therapy. Liver fibrosis scored in liver biopsies or assessed by elastography in 14 patients, after 10 to 24 years with CA therapy, showed a marked improvement with disappearance of cirrhosis (median score < F1; range: F0-F2). CA was well tolerated in all patients, including five women having 10 uneventful pregnancies during treatment. Oral CA therapy is a safe and effective long-term treatment of 3β-HSD and Δ4–3-oxo-R deficiencies and allows affected children to reach adulthood in good health condition without the need for a liver transplantation.

1 January 2012 in Allergologia et Immunopathologia
Verified
Journal Article
Closed access
EBEgidio Barbi
Egidio Barbi
GLG. Longo
G. Longo
IBIrene Berti
Irene Berti
LML. Matarazzo
L. Matarazzo
LRL. Rubert
L. Rubert
AValessandro ventura
alessandro ventura
Specific oral tolerance induction (SOTI) is a promising approach for severe food allergies. There are little data in the literature regarding the home-phase of SOTI, not only with regard to type and frequency of adverse reactions but also regarding the most suitable treatment and protocol. To define the incidence and severity of adverse reactions, possible risk factors, and the safety and effectiveness of the home-phase of an original SOTI protocol in a large group of children with severe cow's milk (CM) allergy, after the hospital "rush" phase. The study was conducted by recording in-home phase adverse events, success and failure as reported by parents, and calling families. Adverse reactions were treated following the International Guidelines, arbitrarily modified by introducing nebulised epinephrine for respiratory reactions, oral beclomethasone for acute gastric pain and oral cromolyn for recurrent gastric pain. Out of 140 patients, 132 were contacted; eight were inaccessible (follow-up 2-84 months). The number of adverse reactions was 1 in every 100 doses. The reactions were treated with nebulised epinephrine (221 reactions), IM epinephrine (6 reactions), and other drugs. Patients with high specific IgE levels (greater than 100 kU(A)/L) and lower CM dose (less than 5 ml) at the end of in-hospital phase showed a higher risk both for number of reactions and use of nebulised epinephrine. The home phase of SOTI was characterised by a significant number of adverse reactions, mostly managed with an acceptable rate of side effects. Nebulised epinephrine played a pivotal role in respiratory reactions.

24 October 2012 in European Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
SSS. Schreiber
S. Schreiber
LRLuca Ronfani
Luca Ronfani
GCG. P. Chiaffoni
G. P. Chiaffoni
LML. Matarazzo
L. Matarazzo
MMM. Minute
M. Minute
EBEgidio Barbi
Egidio Barbi

8 May 2023 in Liver International
Verified
Journal Article
Closed access
AGAngelo Di Giorgio
Angelo Di Giorgio
LMLorenza Matarazzo
Lorenza Matarazzo
ASAurelio Sonzogni
Aurelio Sonzogni
ENEmanuele Nicastro
Emanuele Nicastro
APandrea pietrobattista
andrea pietrobattista
LDLorenzo D'Antiga
Lorenzo D'Antiga

30 April 2020 in JIMD Reports
Verified
Journal Article
Open access
PDF file
LMLorenza Matarazzo
Lorenza Matarazzo
VRValentina Ragnoni
Valentina Ragnoni
CMCristina Malaventura
Cristina Malaventura
ALAlberta Leon
Alberta Leon
DCDavide Colavito
Davide Colavito
GMGiuseppe Maggiore
Giuseppe Maggiore
Glycerol‐3‐phosphate dehydrogenase 1 deficiency is a rare autosomal recessive disorder caused by mutations in the GPD1 gene (GPD1; OMIM*138420). Very few cases are reported in literature. It usually manifests in early infancy with transient hypertriglyceridemia, hepatomegaly, steatosis, and fibrosis. We report the case of a 16‐year‐old boy followed since the age of 1 year for hepatomegaly, elevated liver enzymes, and persistent hypertriglyceridemia. Abdominal ultrasound showed diffuse liver echogenicity and liver biopsy disclosed cirrhosis with micro and macrovesicular steatosis. Next‐generation sequencing for metabolic and genetic liver diseases was conducted with the identification of the homozygous mutation c.895G>A in GPD1 gene resulting in the aminocidic substitution p.G299R. Considering the persistent and progressive increase of plasma triglycerides, fenofibrate treatment was started at 15 years of age allowing triglyceride level reduction in the following 1‐year follow‐up.